Table 1 Clinical and laboratory features of 41 patients with AML, stratified by Twist1 expression level

From: Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia

 

Twist1(+) (n=22)

Twist1(−) (n=19)

P-value

Age (years)

58.1±16.9

62.5±17.6

0.410

Male, n (%)

13 (59.1%)

11 (57.9%)

1.000

WBC (× 109/l)

55.7±75.5

38.4±74.1

0.466

Hemoglobin (g/dl)

7.9±2.3

8.7±2.5

0.325

Platelet count (× 109/l)

47±36

129±206

0.103

Platelet count <150 × 109/l, n (%)

22 (100%)

14 (73.7%)

0.016

ANC<0.5 × 109/l, n (%)

6 (27.3%)

1 (5.3%)

0.099

PB myeloblast ⩾30%, n (%)

17 (77.3%)

7 (36.8%)

0.012

LDH (U/dl)

1071±1976

461±666

0.223

LDH<1.5 × UNL, n (%)

4 (28.6%)

10 (55.6%)

0.086

Uric acid (g/dl)

6.9±4.4

7.0±2.9

0.938

Albumin (g/dl)

2.8±0.7

3.4±0.6

0.024

BM cellularity (%)

86.0±15.4

88.9±14.5

0.541

BM blast (%)

76.0±23.7

72.9±20.6

0.665

BM fibrosis, nil or mild, n (%)

19 (90.5%)

13 (81.3%)

0.634

Extramedullary involvement (+), n (%)

4 (18.2%)

3 (15.8%)

1.000

  1. Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil count; BM, bone marrow; LDH, lactate dehydrogenase; PB, peripheral blood; UNL, upper normal limit; WBC, white blood cell count. Values are reported as mean±s.d. unless otherwise indicated. P-values with statistically significant differences are shown in bold.
Back to article page